Epizyme Inc EPZM:NASDAQ

Last Price$12.96Cboe Previous Close - Real-Time Last Sale as of 3:59PM ET 5/24/19
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$11.92 (5)
Ask (Size)$14.97 (1)
Day Low / HighN/A - N/A
Volume1.1 M
 

View Biotechnology IndustryPeer Comparison as of 05/24/2019

 

Epizyme Inc ( NASDAQ )

Price: $12.96
Change: +0.03 (0.23%)
Volume: 1.1 M
3:59PM ET 5/24/2019
 
 

Veracyte Inc ( NASDAQ )

Price: $24.50
Change: -0.07 (0.28%)
Volume: 451.5 K
4:00PM ET 5/24/2019
 
 

OPKO Health Inc ( NASDAQ )

Price: $1.96
Change: +0.04 (2.08%)
Volume: 2.8 M
4:00PM ET 5/24/2019
 
 

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $12.26
Change: -0.13 (1.05%)
Volume: 283.0 K
4:00PM ET 5/24/2019
 
 

Sangamo Therapeutics Inc ( NASDAQ )

Price: $9.72
Change: +0.26 (2.75%)
Volume: 1.2 M
4:00PM ET 5/24/2019
 

Read more news Recent News

Epizyme Closes Public Offerings of Common Stock, Series A Convertible Preferred Stock
12:50PM ET 3/12/2019 MT Newswires

Epizyme (EPZM) said Tuesday it closed two concurrent underwritten public offerings of 11.5 million shares of its common stock and 350,000 shares of its...

Epizyme Prices Public Offerings of Common Stock, Series A Preferred Stock
11:20AM ET 3/07/2019 MT Newswires

Epizyme (EPZM) on Thursday priced its two concurrent underwritten public offerings of 10 million shares of its common stock and 304,348 shares of its...

Epizyme Plans to Raise Funds via Shares and Convertible Preferred Stock Sales
4:18PM ET 3/06/2019 MT Newswires

Epizyme (EPZM) said on Wednesday it plans to sell shares and Series A convertible preferred stock in two concurrent but separate underwritten public...

Epizyme Reopens Patient Enrollment for Cancer Drug Clinical Trial in France
7:39AM ET 3/01/2019 MT Newswires

Epizyme (EPZM) said Friday in a form 8-K filing with the Securities and Exchange Commission that it has reopened the enrollment of patients in France for...

Company Profile

Business DescriptionEpizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. View company web site for more details
Address400 Technology Square
Cambridge, Massachusetts 02139
Phone+1.617.229.5872
Number of Employees124
Recent SEC Filing05/22/2019CT ORDER
President, Chief Executive Officer & DirectorRobert B. Bazemore
Principal Financial OfficerMatthew E. Ros
Chief Medical OfficerShefali Agarwal
Vice President-Business DevelopmentMichael Boretti

Company Highlights

Price Open$12.55
Previous Close$12.93
52 Week Range$5.14 - 18.70
Market Capitalization$1.2 B
Shares Outstanding90.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/01/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.64
Beta vs. S&P 500N/A
Revenue$21.7 M
Net Profit Margin-401.82%
Return on Equity-48.59%

Analyst Ratings as of 05/17/2019

Buy
9
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset